Showing results (21-30 of 278) with videos related to
Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2011
The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulationFrancesco Pignatti, Iordanis Gravanis, Ralf Herold, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 10, 2011
Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trialsMaria Isaac, Spiros Vamvakas, Eric Abadie, et al.Lancet (London, England)|April 20, 2002
Placebo-controlled trials and the Declaration of HelsinkiJohn A Lewis, Bertil Jonsson, Gottfried Kreutz, et al.Therapeutic Drug Monitoring|May 27, 2003
Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicinKerstin Jönsson-Videsäter, Göran Andersson, Jonas Bergh, et al.Acta Oncologica (Stockholm, Sweden)|July 26, 2006
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancerMia Bergenmar, Urban Nylén, Elisabet Lidbrink, et al.Pharmacogenomics|September 11, 2018
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patientsSarah Sim, Jonas Bergh, Mats Hellström, et al.Histopathology|December 11, 2013
Low concordance of biomarkers in histopathological and cytological material from breast cancerGustav Stålhammar, Gustaf Rosin, Irma Fredriksson, et al.Acta Oncologica (Stockholm, Sweden)|November 11, 2014
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, SwedenLuisa Kessler, Claudette Falato, Sara Margolin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.Cancers|May 8, 2019
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer ImmunotherapySebastian Chrétien, Ioannis Zerdes, Jonas Bergh, et al.Pageof 28